The DURAClone IM T cell subsets tube and MoT assay agreed in 81/83 cases (98%) when classifying patients as CD4+ TEM≥16% or CD4+ TEM<16% Furthermore, the MoT test performed well in predicting hepatitis in a cohort of 16 Stage IV melanoma patients (Figure 6E). This evidence concerns the gene CD4 and hepatitis A virus infection.